RO6885247

Phase 1Small molecule

Roche

RO6885247 is one of 28 small molecule programs targeting Spinal Muscular Atrophy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinal Muscular AtrophyActive, not recruiting

Spinal Muscular AtrophyPhase 1

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Spinal Muscular Atrophy

#DrugCompanyPhaseTrials

Evrysdi

Roche

Approved

8 2

Spinraza

Biogen

Phase 3

20 3

Prilosec

DDexcel Pharma Technologies Ltd.

Amondys 45

Depakote

2 6

Droxia

TTheravia

Phase 2

3 7

Rilutek

AAzurity Pharmaceuticals

Phase 2

1 8

Celebrex

PPhiladelphia Eye Associates

Phase 2

1 9

Onasemnogene Abeparvovec

Novartis

Phase 3

7 10

RO7204239

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Spinal Muscular Atrophy1 trial

A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)

Terminated· Roche logo

Roche·Phase 1·NCT02240355·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RO6885247. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RO6885247 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RO6885247. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

RO6885247

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Spinal Muscular Atrophy1 trial

References

Drug Info

Quick Facts

Related News